| | Anti-vascular endothelial growth factor monotherapy useful option in patients with retinal angiomatous proliferation, study finds
| Stable or improved vision seen in about two-thirds of cases after 2 years; re-treatment needed for most
| | Ophthalmology Times | Anti-vascular endothelial growth factor monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement or stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections. |
| | | | When treating diabetic macular edema, focal/grid photocoagulation more effective than intravitreal triamcinolone, results show
| Patients randomly assigned to receive laser treatment had lower incidence of developing a cataract
| | Ophthalmology Times | | Intravitreal triamcinolone (IVTA) for treating diabetic macular edema (DME) does not seem to be beneficial over the long term compared with focal/grid photocoagulation, and treatment with IVTA results in a higher chance of developing a cataract compared with treatment with the laser, according to a 3-year comparison study. Focal/grid photocoagulation, therefore, remains the most effective treatment for DME, according to one ophthalmologist. |
|
| FDA clears Topcon digital fundus camera
| | Ophthalmology Times E-News | | The FDA has granted 510(k) clearance to a new digital fundus camera (TRC-NW7SF Mark II, Topcon Medical Systems), according to its manufacturer. |
| | Art exhibit focuses on macular degeneration
| | Ophthalmology Times E-News | | To mark the global observance of AMD [age-related macular degeneration] Week, Lighthouse International and AMD Alliance International (AMDAI) will host an exhibit of the works of London-based portrait artist Adam Hahn, whose paintings illustrate how patients with AMD see the world. |
| | | | ANV therapy system receives CE mark approval
| | Ophthalmology Times E-News | | NeoVista Inc. received approval from BSI Product Services to apply the CE mark to its anti-neovascular (ANV) therapy system (Vidion) to treat wet age-related macular degeneration (AMD), the company announced. |
|
| 
Practice Tools
